Tag Archives: Therapeutics

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics  Business Wire Bristol Myers to buy startup Orbital Therapeutics, building out cell therapy pipeline  statnews.com BMS inks $1.5B in vivo CAR-T buyout to pull Orbital into its sphere of influence  Fierce Biotech BMS Makes $1.5B Cell Therapy Play With Orbital Takeover  BioSpace Bristol Myers joins in vivo CAR-T race with …

Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics  Bristol Myers SquibbView Full Coverage on Google News Source link

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion  The Wall Street Journal Novo Nordisk to buy Akero for up to $5.2 billion in new CEO’s revival push  CNBC Novo CEO Says Risk-Taking, Deals Are Needed to Win Obesity Race  Bloomberg.com Novo Nordisk Is Buying Akero Therapeutics. It’s More Good News for Biotech Stocks.  Barron’s Novo buying Akero and its MASH hopeful …

(Reuters) – Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa will receive an upfront payment of $120 million and could earn milestone payments and royalties that lift the total value to as much as $5.7 billion. Shares …

McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, et al. Bipolar disorders. Lancet. 2020;396:1841–56. Article  CAS  PubMed  Google Scholar  Oliva V, Fico G, De Prisco M, Gonda X, Rosa AR, Vieta E. Bipolar disorders: an update on critical aspects. Lancet Reg Health Eur. 2024;48:101135. Article  PubMed  PubMed Central  Google Scholar  Léda-Rêgo G, Studart-Bottó P, Abbade P, …

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Summit Therapeutics may have a geography problem with its lung …

The CRL goes on to suggest that Lykos conduct a new clinical trial in order to address these issues, which it says should focus on: Demonstrating durability of effect Minimising potential for bias Adequately characterising the safety of MDMA The agency provides more specific guidance for each of those broad areas of focus. It also recommended that Lykos “consider an …

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud. You can reach Allison on Signal at AllisonDeAngelis.01. A new oral weight loss drug developed by Viking Therapeutics hit the mark in a mid-stage clinical trial, but the …

Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40%  Bloomberg Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate  Yahoo Finance Viking Therapeutics shares fall 40% on disappointing obesity pill trial data  CNBC High drop-out rate clouds weight loss data for Viking’s oral drug  FirstWord Pharma This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and …

Key Takeaways Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill. Overall, 28% of those taking VK2735 left the Phase 2 trial early compared with 18% among placebo subjects. The research showed the pill reduced the weight of patients who took it for 13 weeks by up to 26.7 pounds. Viking …